九安医疗(002432) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥221,466,258.43, a decrease of 60.93% compared to the same period last year[3] - The net profit attributable to shareholders was -¥4,648,964.24, representing a decline of 104.41% year-on-year[3] - The net profit after deducting non-recurring gains and losses was -¥19,987,588.41, down 119.31% from the previous year[3] - The company's basic earnings per share were -¥0.0101, a decrease of 104.15% year-on-year[3] - The company experienced a 50.82% decrease in revenue compared to the previous year, primarily due to reduced sales of pandemic-related products[7] - The company’s investment income decreased by 82.66% to ¥52,264,764.23, reflecting a significant drop in returns from invested funds[7] - Total operating revenue for the current period is ¥790,459,426.03, a decrease of 50.8% compared to ¥1,607,397,400.79 in the previous period[17] - Net profit for the current period is ¥13,934,765.35, a significant decline of 96.8% from ¥434,940,236.68 in the previous period[18] - Basic earnings per share for the current period is ¥0.1102, compared to ¥0.8388 in the previous period, reflecting a decrease of 86.9%[19] - Total comprehensive income attributable to the parent company's owners is ¥32,163,560.08, down 91.2% from ¥363,371,175.25 in the previous period[19] Cash Flow - Cash flow from operating activities was -¥72,724,140.89, a decline of 117.74% compared to the same period last year[3] - Cash inflow from operating activities totals ¥834,793,821.74, down 51.1% from ¥1,710,994,803.25 in the previous period[20] - The net cash flow from operating activities was -72,724,140.89 CNY, a significant decrease compared to 410,024,357.59 CNY in the previous period[21] - Total cash outflow from operating activities reached 907,517,962.63 CNY, compared to 1,300,970,445.66 CNY in the previous period[21] - The net cash flow from investing activities was -445,883,306.90 CNY, contrasting with a positive 50,810,950.43 CNY in the previous period[21] - Cash inflow from financing activities totaled 639,094,867.35 CNY, a substantial increase from 172,633,624.37 CNY in the previous period[21] - The net cash flow from financing activities was 148,347,743.04 CNY, compared to 88,892,772.75 CNY in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,521,245,313.69, an increase of 2.55% compared to the end of the previous year[4] - The company reported a total asset value of RMB 2,521,245,313.69, compared to RMB 2,458,560,510.72 in the previous period[16] - The company's total liabilities amounted to RMB 610,169,292.31, a decrease from RMB 636,093,577.60 in the previous period[15] - The total liabilities were 499,162,488.67 CNY, remaining unchanged from the previous period[24] - Total liabilities amounted to CNY 636,093,577.60, a decrease of CNY 10,005,317.69 from the previous period[25] - Non-current liabilities totaled CNY 136,931,088.93, down from CNY 146,936,406.62 in the prior period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,131[9] - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, holds a 22.88% stake, amounting to 109,497,902 shares[10] - The company completed a private placement of 45,797,101 shares at a price of RMB 6.90 per share, raising a total of RMB 315,999,996.90, with a net amount of RMB 309,369,294.14 after expenses[12] - The company repurchased 11,873,630 shares, accounting for 2.48% of the total share capital, with a total transaction amount of RMB 99,834,465.77, at prices ranging from RMB 7.94 to RMB 9.03 per share[12] - The company repurchased an additional 13,611,451 shares, representing 2.84% of the total share capital, with a total transaction amount of RMB 99,941,563.70, at prices ranging from RMB 7.08 to RMB 7.64 per share[12] Research and Development - The company reported a significant increase in development expenditures, rising by 316.63% to ¥34,703,432.45 due to increased capitalized R&D investments[7] - Research and development expenses for the current period are ¥94,526,560.35, slightly up from ¥94,102,262.82 in the previous period[17] Other Financial Metrics - The company’s weighted average return on equity was -0.23%, a decrease of 5.55% compared to the previous year[3] - The company reported a credit impairment loss of ¥-302,748.43, which was a change of 97.58% compared to the previous period[8] - The company distributed a cash dividend of RMB 0.6 per 10 shares, totaling RMB 28,003,763.52, based on a total share base of 466,729,392 shares[12] - The company has implemented new leasing standards affecting the financial statements, indicating a strategic adjustment in financial reporting[22] - The report indicates that the new leasing standards were not applicable for the current period[25] - The report was released on October 27, 2021, by the company's legal representative Liu Yi[25]